Skip to search formSkip to main contentSkip to account menu

alemtuzumab Injection [Lemtrada]

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system which leads to demyelination and neurodegeneration… 
2019
2019
Tras finalizar la evaluacion europea del balance beneficio-riesgo de alemtuzumab (Lemtrada®) se recomienda restringir la… 
2019
2019
La gravedad de los casos identificados ha motivado el inicio de una revisión detallada de la información disponible a nivel… 
2017
2017
U pstream targeting of both T and B cells is a rational therapeutic approach in multiple sclerosis (MS) in view of how both cell… 
2016
2016
BackgroundAlemtuzumab (Lemtrada®) is a newly approved therapeutic agent for relapsing-remitting multiple sclerosis (RRMS). In… 
2016
2016
Twenty-four approved monoclonal antibodies (mAbs) not indicated for cancer therapy are specific for a total of 20 different… 
2015
2015
  • 2015
  • Corpus ID: 58898003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, today announced posit ive new five-year investigational data from…